首页> 外文期刊>Pain research & management: the journal of the Canadian Pain Society = journal de la socie?te? canadienne pour le traitement de la douleur >Efficacy and Safety of Transdermal Buprenorphine versus Oral Tramadol/Acetaminophen in Patients with Persistent Postoperative Pain after Spinal Surgery
【24h】

Efficacy and Safety of Transdermal Buprenorphine versus Oral Tramadol/Acetaminophen in Patients with Persistent Postoperative Pain after Spinal Surgery

机译:脊柱手术后持续术后疼痛患者透皮丁丙诺啡与口服曲马多酚/乙酰氨基酚的疗效和安全性

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose. Control of persistent pain following spinal surgery is an unmet clinical need. This study compared the efficacy and safety of buprenorphine transdermal system (BTDS) to oral tramadol/acetaminophen (TA) in Korean patients with persistent, moderate pain following spinal surgery. Methods. Open-label, interventional, randomized multicenter study. Adults with persistent postoperative pain (Numeric Rating Scale [NRS] ≥ 4 at 14–90 days postsurgery) were enrolled. Patients received once-weekly BTDS (n=47; 5?μg/h titrated to 20?μg/h) or twice-daily TA (n=40; tramadol 37.5?mg/acetaminophen 325?mg, one tablet titrated to 4 tablets) for 6 weeks. The study compared pain reduction with BTDS versus TA at week 6. Quality of life (QoL), treatment satisfaction, medication compliance, and adverse events (AEs) were assessed. Findings. At week 6, both groups reported significant pain reduction (mean NRS change: BTDS ?2.02; TA ?2.76, both P<0.0001) and improved QoL (mean EQ-5D index change: BTDS 0.10; TA 0.19, both P<0.05). The BTDS group achieved better medication compliance (97.8% versus 91.0%). Incidence of AEs (26.1% versus 20.0%) and adverse drug reactions (20.3% versus 16.9%) were comparable between groups. Implications. For patients with persistent pain following spinal surgery, BTDS is an alternative to TA for reducing pain and supports medication compliance. This trial is registered with Clinicaltrials.gov: NCT01983111.
机译:目的。脊髓手术后持续疼痛的控制是一种未满足的临床需求。该研究将丁丙诺啡透皮系统(BTDS)对脊髓手术持续,中度疼痛患者口服曲马多的曲调/乙酰氨基酚(TA)的疗效和安全性。方法。开放标签,介入,随机多中心研究。患有持续术后疼痛的成年人(数字评级规模[NRS]≥4在14-90天后的第14-90天)进行了注册。患者每周接受一次(n = 47; 5?μg/ h滴定到20≤μg/ h)或两次 - 每日Ta(n = 40;曲马多37.5×mg /乙酰氨基酚325?mg,一种滴定滴定到4片的片剂)6周。该研究在第6周与BTDS与TA相比疼痛减少6.寿命质量(QOL),治疗满意度,药物合规性和不良事件(AES)进行了评估。发现。第6周,两组均报告减少显着疼痛(平均值,改变:BTDS?2.02; TA?2.76,P <0.0001)和改进的QOL(平均值EQ-5D指数变化:BTDS 0.10; TA 0.19,B <0.19) 。 BTDS组达到了更好的药物合规性(97.8%,而91.0%)。 AE的发病率(26.1%与20.0%)和不良药物反应(20.3%对16.9%)在组之间相当。含义。对于脊柱手术后持续疼痛的患者,BTD是减少疼痛的替代方案,并支持药物遵守。此试验在ClinicalTrials.gov注册:NCT01983111。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号